search
Back to results

BiOSENCY BORA Band SpO2 Validation Study

Primary Purpose

Hypoxia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BORA Band SpO2 Validation Study
Sponsored by
Biosency
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Hypoxia focused on measuring Pulse oximetry

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either
  • Subject must have the ability to understand and provide written informed consent
  • Subject is 18 to 50 years of age
  • Subject must be willing and able to comply with study procedures and duration
  • Subject is a non-smoker or who has not smoked within 2 days prior to the study
  • Wrist size should be between 15-23 cm (5.9 - 9 inches)

Exclusion Criteria:

  • Subject is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
  • Female subjects that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential).
  • Smoker Subjects who have refrained will be screened for COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)

  • Subjects with known respiratory conditions such as: (self-reported)

    • uncontrolled / severe asthma,
    • flu,
    • pneumonia / bronchitis,
    • shortness of breath / respiratory distress,
    • unresolved respiratory or lung surgery with continued indications of health issues ,
    • emphysema, COPD, lung disease

  • Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)

    • hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during health screen).
    • have had cardiovascular surgery
    • Chest pain (angina)
    • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
    • previous heart attack
    • blocked artery
    • unexplained shortness of breath
    • congestive heart failure (CHF)
    • history of stroke
    • transient ischemic attack
    • carotid artery disease
    • myocardial ischemia
    • myocardial infarction
    • cardiomyopathy

  • Self-reported health conditions as identified in the Health Assessment Form (self-reported)

    • diabetes,
    • uncontrolled thyroid disease,
    • kidney disease / chronic renal impairment,
    • history of seizures (except childhood febrile seizures),
    • epilepsy,
    • history of unexplained syncope,
    • recent history of frequent migraine headaches,
    • recent symptomatic head injury (within the last 2 months)
    • cancer / chemotherapy

  • Subjects with known clotting disorders (self-reported)

    • history of bleeding disorders or personal history of prolonged bleeding from injury
    • history of blood clots
    • hemophilia
    • current use of blood thinner: prescription or daily use of aspirin
  • Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
  • Subjects with severe allergies to iodine (only applicable if iodine is used)
  • Subjects with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
  • Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio < 0.4)
  • Unwillingness or inability to remove colored nail polish from test digits.
  • Other known health condition, should be considered upon disclosure in health assessment form
  • Wrist size should be between 15-23 cm (5.9 - 9 inches)

Sites / Locations

  • Clinimark Desaturation Laboratory

Outcomes

Primary Outcome Measures

Accuracy of BORA Band SpO2 measurements versus arterial blood co-oximetry
Accuracy of the BORA Band SpO2 measurement as compared to reference co-oximetry performed on arterial blood samples. Results shall include SpO2 Root mean square accuracy of BORA Band SpO2 Bias of BORA Band Bland-Altman plots with linear regression line and 95% upper and lower limits of agreement
Accuracy of BORA Band Pulse Rate measurements versus electrocardiogram readings
Accuracy of the BORA Band pulse rate measurement as compared to reference electrocardiogram readings. Results shall include Pulse rate Root mean square accuracy of BORA Band Pulse rate Bias of BORA Band

Secondary Outcome Measures

Full Information

First Posted
April 4, 2019
Last Updated
April 15, 2019
Sponsor
Biosency
Collaborators
Clinimark, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT03918018
Brief Title
BiOSENCY BORA Band SpO2 Validation Study
Official Title
SpO2 and Pulse Rate Accuracy Comparison of BiOSENCY BORA Band to Arterial Blood CO-Oximetry and Reference ECG
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
February 19, 2019 (Actual)
Primary Completion Date
February 21, 2019 (Actual)
Study Completion Date
February 21, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biosency
Collaborators
Clinimark, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this clinical study is to validate the SpO2 accuracy of the BiOSENCY BORA BAND™ wristband Pulse Oximeter during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. The end goal is to provide supporting documentation for the SpO2 accuracy validation of BORA BAND™ wristband Pulse Oximeter. It is required that the Accuracy Root Mean Square (ARMS) performance of the BORA BAND™ wristband Pulse Oximeter will meet a specification of 3.5 or better in non-motion conditions for the range of 70 - 100% SpO2 thereby demonstrating an acceptable SpO2 accuracy performance specification.
Detailed Description
The SpO2 accuracy performance of BiOSENCY BORA BAND™ wristband Pulse Oximeter will be evaluated during non-motion conditions over the range of 70-100% SaO2 and compared to arterial blood samples assessed by CO-Oximetry. A minimum of 10 healthy adult male and female subjects, ranging in age and pigmentation from light to dark, will be enrolled in the study to meet the study design requirements defined by ISO 80601-2-61:2017 and by the FDA's Guidance for Pulse Oximeters (March 4, 2013). The subjects will have an arterial catheter placed in the radial artery to allow for simultaneous blood samples during stable plateaus of induced hypoxic levels. The investigational device will be placed on the wrist opposite for the test per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter. For the data analysis, the control oximeter will be used to assess the stability of each data point. Data that is found to be unstable will be removed prior to the comparative analysis. The CO-Oximeter data will be reviewed to make sure it does not contain any anomalous values such as elevated, low or inconsistent COHb, MetHb, or tHb data. Anomalous values will be removed from the analysis prior to pairing of the SpO2 and SaO2 data. The statistical analysis is performed on a minimum of 200 data points collected from at least 10 subjects for the range of 70% to 100% SaO2 with allowance of ± 3% of the target range. Functional SaO2 as measured by Reference CO-Oximetry will be used as the basis for comparison. The Accuracy Root Mean Square (ARMS) calculation is used to determine the SpO2 accuracy performance. Success will be achieved with an ARMS of 3.5 or better showing equivalence to the Gold Standard Reference CO-Oximetry providing documentation to support SpO2 accuracy claims for the investigational device. The study population will include 10-15 healthy non-smoking (or has refrained from smoking for 2 days) competent adults, 18-50 years of age. The subject selection will be an equitable distribution of males and females of any race with varying skin tones including at least 2 darkly pigmented subjects or 15% of the subject pool, whichever is larger. The subjects must understand the study and consent to participate by signing the Informed Consent Form. The subjects must be healthy showing no evidence of medical problems as indicated by satisfactorily completing the health assessment form.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoxia
Keywords
Pulse oximetry

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
BORA Band SpO2 Validation Study
Intervention Description
Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk. Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%. The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects.
Primary Outcome Measure Information:
Title
Accuracy of BORA Band SpO2 measurements versus arterial blood co-oximetry
Description
Accuracy of the BORA Band SpO2 measurement as compared to reference co-oximetry performed on arterial blood samples. Results shall include SpO2 Root mean square accuracy of BORA Band SpO2 Bias of BORA Band Bland-Altman plots with linear regression line and 95% upper and lower limits of agreement
Time Frame
1 day
Title
Accuracy of BORA Band Pulse Rate measurements versus electrocardiogram readings
Description
Accuracy of the BORA Band pulse rate measurement as compared to reference electrocardiogram readings. Results shall include Pulse rate Root mean square accuracy of BORA Band Pulse rate Bias of BORA Band
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either Subject must have the ability to understand and provide written informed consent Subject is 18 to 50 years of age Subject must be willing and able to comply with study procedures and duration Subject is a non-smoker or who has not smoked within 2 days prior to the study Wrist size should be between 15-23 cm (5.9 - 9 inches) Exclusion Criteria: Subject is considered as being morbidly obese (defined as BMI >39.5) Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.) Female subjects that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential). Smoker Subjects who have refrained will be screened for COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow) Subjects with known respiratory conditions such as: (self-reported) uncontrolled / severe asthma, flu, pneumonia / bronchitis, shortness of breath / respiratory distress, unresolved respiratory or lung surgery with continued indications of health issues , emphysema, COPD, lung disease Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review) hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during health screen). have had cardiovascular surgery Chest pain (angina) heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen) previous heart attack blocked artery unexplained shortness of breath congestive heart failure (CHF) history of stroke transient ischemic attack carotid artery disease myocardial ischemia myocardial infarction cardiomyopathy Self-reported health conditions as identified in the Health Assessment Form (self-reported) diabetes, uncontrolled thyroid disease, kidney disease / chronic renal impairment, history of seizures (except childhood febrile seizures), epilepsy, history of unexplained syncope, recent history of frequent migraine headaches, recent symptomatic head injury (within the last 2 months) cancer / chemotherapy Subjects with known clotting disorders (self-reported) history of bleeding disorders or personal history of prolonged bleeding from injury history of blood clots hemophilia current use of blood thinner: prescription or daily use of aspirin Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported) Subjects with severe allergies to iodine (only applicable if iodine is used) Subjects with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine) Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio < 0.4) Unwillingness or inability to remove colored nail polish from test digits. Other known health condition, should be considered upon disclosure in health assessment form Wrist size should be between 15-23 cm (5.9 - 9 inches)
Facility Information:
Facility Name
Clinimark Desaturation Laboratory
City
Louisville
State/Province
Colorado
ZIP/Postal Code
80027
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

BiOSENCY BORA Band SpO2 Validation Study

We'll reach out to this number within 24 hrs